# Safety and Efficacy of the Bacteriophage Preparation, ShigActive™, in a Human Experimental Model of Shigellosis

> **NCT05182749** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Intralytix, Inc.** · enrollment: 52 (estimated)

## Conditions studied

- Shigellosis

## Interventions

- **BIOLOGICAL:** bacteriophage
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05182749
- **Lead sponsor:** Intralytix, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-02-23
- **Primary completion:** 2024-12-09
- **Final completion:** 2025-09-30
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2025-06-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05182749

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05182749, "Safety and Efficacy of the Bacteriophage Preparation, ShigActive™, in a Human Experimental Model of Shigellosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05182749. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*